Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Cash from Operations: 2014-2024

Historic Cash from Operations for Editas Medicine (EDIT) over the last 11 years, with Dec 2024 value amounting to -$210.3 million.

  • Editas Medicine's Cash from Operations rose 41.35% to -$30.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$179.6 million, marking a year-over-year increase of 1.18%. This contributed to the annual value of -$210.3 million for FY2024, which is 59.09% down from last year.
  • Latest data reveals that Editas Medicine reported Cash from Operations of -$210.3 million as of FY2024, which was down 59.09% from -$132.2 million recorded in FY2023.
  • Over the past 5 years, Editas Medicine's Cash from Operations peaked at -$132.2 million during FY2023, and registered a low of -$210.3 million during FY2024.
  • For the 3-year period, Editas Medicine's Cash from Operations averaged around -$173.3 million, with its median value being -$177.3 million (2022).
  • Its Cash from Operations has fluctuated over the past 5 years, first slumped by 342.21% in 2020, then climbed by 25.47% in 2023.
  • Editas Medicine's Cash from Operations (Yearly) stood at -$179.8 million in 2020, then increased by 8.92% to -$163.8 million in 2021, then declined by 8.27% to -$177.3 million in 2022, then climbed by 25.47% to -$132.2 million in 2023, then slumped by 59.09% to -$210.3 million in 2024.